… To help address some of these concerns and provide advice regarding the appropriate
place of these medicines in clinical practice, the Improving Diabetes Steering Committee was …

… Due to its insulin-independent mechanism, treatment with SGLT2-inhibitors … SGLT2-inhibitors
for treatment of T2DM. We more specifically focus on dapagliflozin, the first SGLT2-inhibitor …

Sodium-glucose cotransporter-2 inhibitors (SGLT-2i), initially studied and approved for the
treatment of diabetes, are now becoming a promising class of agents to treat heart failure (HF) …

… Inhibiting SGLT2 activity is accompanied by glycosuria and osmotic diuresis. … SGLT2
activity accounts for up to 90% of renal glucose reabsorption, in clinical practice SGLT2 inhibitors …

… , restrictive inclusion criteria make study results less applicable, due to the lack of similarity
between study participants and the vast majority of patients encountered in clinical practice. …

… Having discussed the direct effects of SGLT2 inhibition on the kidney at length, in this
subsection, we will acknowledge the many indirect effects of SGLT2 inhibition on the kidney, …

… of SGLT-2is in routine clinical practice, specifically their … clinical ramifications of SGLT-2i
therapy in clinical practice for the prevention and treatment of HF, with a focus on current clinical …

… Our results extend these findings to a population that more closely mirrors the use of SGLT2
inhibitors in clinical practice, where this class is still predominantly prescribed to patients …

… We follow this approach in clinical practice, stopping an SGLT2i only when adverse effects …
The authors were members of the writing group for the 2020 KDIGO clinical practice guideline …

… Unlike the insulin secretagogues and insulin sensitizers, the action of SGLT2 inhibitors is …
in hypoglycemic events was noted in clinical trials of SGLT2 inhibitors as will be discussed …